Tag Archive for: Servier

eb-20260309-mohamed-nohassi-Jthv-V45G0E-unsplashUnsplash+
M&A

Servier buys Day One for $2.5bn to bolster its rare cancer pipeline

French pharma giant Servier is spending US$2.5bn to snap up Day One Biopharmaceuticals, gaining a key approved drug for difficult childhood brain tumours along with several promising pipeline candidates.

Read more
servier insilico
R&D collaborations

Servier and Insilico sign an $888 million AI oncology discovery deal

On January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for a multi-year research and development collaboration to discover and develop oncology therapies using Insilico’s artificial intelligence (AI)-driven drug discovery platform and Servier’s cancer development expertise.

Read more
The Fragile X mutation is a type of genetic mutation called a repeat expansion. This repeat expansion occurs on the FMR1 gene, on the long arm of the X chromosome leading to gene silencing if more than 200 repeats occur.FRAXA Ewsearch Organisation
Partnership

Servier acquires Kaerus Bioscience’s FXS candidate for US$450m

In a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.

Read more